Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

356 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.
Alikian M, Gerrard G, Subramanian PG, Mudge K, Foskett P, Khorashad JS, Lim AC, Marin D, Milojkovic D, Reid A, Rezvani K, Goldman J, Apperley J, Foroni L. Alikian M, et al. Among authors: rezvani k. Am J Hematol. 2012 Mar;87(3):298-304. doi: 10.1002/ajh.22272. Epub 2012 Jan 9. Am J Hematol. 2012. PMID: 22231203 Free article. Review.
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib.
Khorashad JS, Wagner S, Greener L, Marin D, Reid A, Milojkovic D, Patel H, Willimott S, Rezvani K, Gerrard G, Loaiza S, Davis J, Goldman J, Melo J, Apperley J, Foroni L. Khorashad JS, et al. Among authors: rezvani k. Haematologica. 2009 Jun;94(6):861-4. doi: 10.3324/haematol.2008.003715. Epub 2009 Apr 18. Haematologica. 2009. PMID: 19377081 Free PMC article.
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW, Szydlo R, Bua M, Foroni L, Reid A, Khorashad JS, de Lavallade H, Rezvani K, Paliompeis C, Goldman JM, Marin D. Milojkovic D, et al. Among authors: rezvani k. Haematologica. 2010 Feb;95(2):224-31. doi: 10.3324/haematol.2009.012781. Epub 2009 Oct 14. Haematologica. 2010. PMID: 19833633 Free PMC article.
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS. Marin D, et al. Among authors: rezvani k. J Clin Oncol. 2010 May 10;28(14):2381-8. doi: 10.1200/JCO.2009.26.3087. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385986 Free PMC article.
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
Chaidos A, Patterson S, Szydlo R, Chaudhry MS, Dazzi F, Kanfer E, McDonald D, Marin D, Milojkovic D, Pavlu J, Davis J, Rahemtulla A, Rezvani K, Goldman J, Roberts I, Apperley J, Karadimitris A. Chaidos A, et al. Among authors: rezvani k. Blood. 2012 May 24;119(21):5030-6. doi: 10.1182/blood-2011-11-389304. Epub 2012 Feb 27. Blood. 2012. PMID: 22371885 Free PMC article.
Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K, Popat UR, Shpall EJ, Champlin RE, Oran B. Yalniz FF, et al. Among authors: rezvani k. Cancer. 2020 May 15;126(10):2183-2192. doi: 10.1002/cncr.32769. Epub 2020 Feb 26. Cancer. 2020. PMID: 32101640 Free article.
Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.
Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Bassett R, Lyons G, Chen J, Rezvani K, Popat U, Kebriaei P, Patel K, Rondon G, Shpall EJ, Champlin RE. Oran B, et al. Among authors: rezvani k. Haematologica. 2017 Jan;102(1):110-117. doi: 10.3324/haematol.2016.144253. Epub 2016 Aug 18. Haematologica. 2017. PMID: 27540139 Free PMC article.
CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia.
Pasvolsky O, Daher M, Alatrash G, Marin D, Daver N, Ravandi F, Rezvani K, Shpall E, Kebriaei P. Pasvolsky O, et al. Among authors: rezvani k. Front Oncol. 2022 Jan 10;11:800110. doi: 10.3389/fonc.2021.800110. eCollection 2021. Front Oncol. 2022. PMID: 35083154 Free PMC article. Review.
Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia.
Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Shah MV, et al. Among authors: rezvani k. Biol Blood Marrow Transplant. 2018 Jul;24(7):1514-1520. doi: 10.1016/j.bbmt.2018.02.003. Epub 2018 Feb 12. Biol Blood Marrow Transplant. 2018. PMID: 29448058 Free article.
356 results